The purpose of the present study was to assess the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan against locally advanced lower rectal cancer WT (n = 26), heterozygous (n = 15), and homozygous (n = 5) groups, the latter including double heterozygosities. We evaluated associations between clinical characteristics, including UGT1A1 polymorphisms, and chemoradiotherapy efficacy and toxicity.
Incidence rates of grade 3+ neutropenia and diarrhea were 17.0% and 30.4%, respectively. Relative dose intensity was 89.3%. Pathological complete response rate (grade 3) was 26.1%, and the good response (grade 2/3) rate was 84.8%. UGT1A1 polymorphisms were significantly associated with neutropenia and pathological good responses, but not with diarrhea. UGT1A1 polymorphism was the only predictive factor for pathological good responses. Our results indicate that UGT1A1 polymorphism is a predictive factor to determine the clinical efficacy of preoperative chemoradiotherapy and hematological toxicity induced by chemoradiotherapy using irinotecan in locally advanced rectal cancer patients.
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| INTRODUC TI ON
Colorectal cancer (CRC) is one of the most common malignancies, and the number of CRC patients has been increasing an- However, no study has assessed the association between UGT1A1 polymorphisms and chemoradiotherapy because patients with homozygosity or double heterozygosities were excluded from previous clinical trials. 12, 13, 21 In the present study, we assessed the associations between preoperative S-1 plus irinotecan chemoradiotherapy for lower rectal cancer and UGT1A1 polymorphisms including homozygosity and double heterozygosities. We included patients with these mutations because other studies found that the risk of severe toxicity was not higher in these patients than in WT patients when <150 mg/ 
| Classification of UGT1A1 polymorphisms
UGT1A1 polymorphisms were assessed after consulting with a specialist of hereditary diseases. Blood samples were obtained from patients scheduled to undergo irinotecan treatment, and UGT1A1*28 and UGT1A1*6 were analyzed using the Invader assay (SRL Inc., Kobe, Japan). Polymorphisms were classified into three groups: WT (*1/*1), heterozygous (*28/*1, *6/*1), and homozygous (*28/*28, *6/*6, *28/*6). Double heterozygosities (*28/*6) were classified in the homozygous group because of the reported possible serious toxicities associated with double heterozygosities. 
| Surgical procedure
All patients underwent total mesorectal excision, which included low anterior resection followed by double-stapling technique for reconstruction, intersphincteric resection, and APR. Diverting ileostomy was routinely constructed for all cases, except those with APR. If the involvement of adjacent organs was diagnosed before preoperative chemoradiotherapy, en bloc resection of primary tumors was carried out. Lateral lymph node (LLN) dissection was carried out when lateral lymph nodes were >7 mm determined by MRI before preoperative chemoradiotherapy.
| Association between UGT1A1 polymorphisms and clinicopathological features
The 
| Association between UGT1A1 polymorphisms and toxicity or relative dose intensity
Hematological and non-hematological toxicities from preopera- 
| Associations with pathological response
We further analyzed predictors of pathological good response by selecting six candidate factors including pretreatment clinical T stage, pretreatment clinical N stage, histology, CEA before chemoradiotherapy, mGPS before chemoradiotherapy, and UGT1A1 polymorphisms. mGPS was classified using C-reactive protein levels (CRP:
>0.5 mg/dL) and serum albumin levels (<3.5 mg/day). 
| RE SULTS

| UGT1A1 polymorphisms
We examined UGT1A1 polymorphisms in the 46 patients in the present study. The distribution of UGT1A1*6 and UGT1A1*28 polymorphisms is shown in Table 1 . Twenty-six patients (56.5%), 15 patients (32.6%), and five patients (10.9%) were classified into the WT, heterozygous (nine *1/*6 and six *1/*28), and homozygous groups, respectively. The homozygous group consisted of two homozygous patients (one *6/*6 and one *28/*28) and three double heterozygous patients (*6/*28). The allele frequencies of UGT1A1 *6 and *28 were calculated as 15.3% and 12.0%, respectively. Genotype frequencies did not significantly deviate from the Hardy-Weinberg equilibrium (P = 0.38).
| Associations between clinicopathological features and UGT1A1 polymorphisms
Clinical features are listed in Table 3 .
Among the patients treated with preoperative chemoradiotherapy, 71.7% were downstaged according to the UICC criteria. Five patients (10.9%) were grade 1a (all in the WT group), two (4.3%) were grade 1b (all in the WT group), 27 (58.7%) were grade 2 (13 in the WT group, 11 in the heterozygous group, and three in the homozygous group), and 12 (26.1%) were grade 3 (six in the WT group, four in the heterozygous group, and two in the homozygous group). There were no significant differences in pathological features between the UGT1A1 polymorphism groups.
| Association between toxicity and UGT1A1 polymorphisms
Toxicities are listed in Table 4 . We observed a significant difference in the incidence of leukopenia and neutropenia in the UGT1A1 polymorphism groups.
Grade 3-4 leukopenia and neutropenia did not occur in WT patients. Patients in the heterozygous and homozygous groups had more grade 3-4 neutropenia and leukopenia than those in the WT patient group (P < .05). However, there was no significant difference in the incidence of other factors, including diarrhea, liver function, and renal function, among the three groups. 
| Association between RDI and UGT1A1 polymorphisms
Relative dose intensities are listed in Table 4 . Each UGT1A1 group showed >90% RDI in those receiving S-1, 88% in those receiving irinotecan, and 99% in those receiving radiation therapy. There was no significant difference in RDI according to UGT1A1 polymorphism despite the significant differences observed in hematological toxicities.
| Associations with pathological responses
Associations between representative candidate factors and pathological responses are listed in Table 5 . Only UGT1A1 polymorphisms were significantly associated with good tumor response by preoperative chemoradiotherapy (P = .014) ( Table 5 ). All patients in the heterozygous and homozygous groups showed a good response (grade 2/3) following preoperative chemoradiotherapy.
| D ISCUSS I ON
In the present study, we showed that UGT1A1 polymorphisms were the only factor for predicting a good pathological response to preoperative chemoradiotherapy using irinotecan in patients with locally advanced rectal cancer. To our knowledge, this is the first study to evaluate the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan according to UGT1A1 polymorphisms. 
TA B L E 3 Summary of pathological outcomes by UGT1A1 group
Our study showed that the allele frequencies of UGT1A1 *6 and *28 were 15.3% and 12.0%, respectively. Genotype frequencies did not deviate significantly from Hardy-Weinberg equilibrium. Miyata et al 20 reported that the allele frequencies of UGT1A1 *6 and *28 were 16.7% and 12.6%, respectively, in 795 Japanese prospective studies. Thus, the frequencies of UGT1A1 *6 and *28 in our report were comparable to the data previously reported in Japanese patients.
Our preoperative chemoradiotherapy using S-1 plus irinotecan was designed to increase the ypCR rate compared with conventional preoperative chemoradiotherapy using 5-FU-based chemotherapy that the proportion of good responders increased linearly with the increased dose of irinotecan. Importantly, the presence of UGT1A1 polymorphisms was not assessed in these reports. [12] [13] [14] [15] Therefore, our study is the first to report on preoperative irinotecan-based chemoradiotherapy while also grouping the patients by UGT1A1 polymorphisms without excluding any patient groups.
In Western countries, UGT1A1 polymorphisms have been confirmed to be a predictor of toxicity to irinotecan. ALT, alanine aminotransferase; AST, aspartate aminotransferase; RDI, relative dose intensity; RT, radiation therapy; UGT1A1, UDP-glucuronosyltransferase 1A1. The factor showing the significant difference is bold value. a P-values were calculated for grade 3-4 toxicity using Fisher's exact test when present in at least one patient from any UGT1A1 group; otherwise, P-values were calculated using an analysis of variance model. En-dash in the column of the "P-value" indicates that no grade 3-4 toxicity occurred in any UGT1A1 polymorphisms.
because of severe hematological toxicity and diarrhea. 32 In Japan, increased cases of neutropenia were reported in patients who received FOLFIRI for CRC or combination chemotherapy of irinotecan and cisplatin for lung cancer and gastric cancer. 20, 33, 34 The influence of UGT1A1 polymorphisms on the therapeutic effect of irinotecan has been investigated much less than toxicity, although Xu et al and Toffoli et al 35, 36 reported differences in the clinical responses to irinotecan-based chemotherapy in advanced CRC patients with UGT1A1*28 genotype mutations. In addition,
Han et al 37 showed that patients with homozygous UGT1A1*6 were associated with tumor response rates. However, the usefulness of UGT1A1 polymorphisms in predicting response to chemoradiotherapy has not been well investigated.
In the present study, patients with UGT1A1 mutations showed a significantly better response to chemoradiotherapy (including irinotecan) than those without these mutations. Moreover, univariate analysis using CEA and mGPS, which were reported as biomarkers for chemoradiotherapy, 25, [38] [39] [40] identified that only UGT1A1 polymorphisms were a predictive factor for pathologically good response.
In terms of toxicity, in the present study, only the incidence of neutropenia was significantly affected by UGT1A1 polymorphisms. Indeed, the incidence of diarrhea, a critical symptom of toxicity that is significantly worsened by UGT1A1 mutations in chemotherapy regimens, 35 was not affected. The incidence of grade 3+ diarrhea was 29.3% in this study, which was higher than the 4.5% reported by Sato et al, 12 the 5.7%
seen by Jung et al, 14 and the 11.1% observed in the SAMRAI-1 trial. 26 This high incidence rate may reflect the larger area being exposed to radiotherapy and insufficient prophylactic treatment for diarrhea. 12, 14, 26 There were several limitations to the present study; first, it was a retrospective study in which UGT1A1 polymorphism analysis was CEA levels before CRT TA B L E 5 Associations between UGT1A1 polymorphisms and the clinical efficacy of preoperative chemoradiotherapy not carried out for all patients receiving preoperative chemoradiotherapy (including irinotecan). Second, it was a relatively small study carried out in a single institute with no adjustment for clinical background. Finally, the follow-up time was not sufficient to evaluate long-term efficacy according to UGT1A1 polymorphisms.
Our results indicate that UGT1A1 polymorphism is a predictive factor to determine the clinical efficacy of preoperative chemoradiotherapy and hematological toxicity induced by chemoradiotherapy using irinotecan in locally advanced rectal cancer patients.
A randomized multicenter study could elucidate the influence of dose setting by UGT1A1 polymorphism on efficacy and toxicity of preoperative chemoradiotherapy using irinotecan for rectal cancer patients.
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